Ocugen’s stock was up more than 6% in early afternoon trading Tuesday after the Malvern biopharmaceutical company announced the publication of positive pediatric clinical testing results for the Covid-19 vaccine it is attempting to bring to North America.
Early last year, Ocugen (NASDAQ: OCGN) formed a partnership with Bharat Biotech of India for Covaxin, a Covid vaccine develop by Bharat that is approved in India and about two dozen other countries. Under the partnership, Ocugen is working to…
